Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CFD | P00746 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 5/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080189 | 0.89 | BTK (0.44) | BTKHDAC6KDM4ECFD | |
| SCHEMBL4080605 | 0.88 | BTK (0.43) | BTKHDAC6POLBTDP1CFD | |
| SCHEMBL4095334 | 0.84 | BTK (0.38) | BTKHDAC6CFDSYK | |
| SCHEMBL2996263 | 0.83 | HDAC6 (0.41) | BTKHDAC6SYK | |
| SCHEMBL13771354 | 0.81 | BTK (0.54) | BTKHDAC6 | |
| SCHEMBL13821341 | 0.81 | BTK (0.54) | BTKHDAC6 | |
| SCHEMBL13771751 | 0.81 | BTK (0.47) | BTKHDAC6POLBTDP1SYK | |
| SCHEMBL13765441 | 0.81 | BTK (0.49) | BTKKDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL4090596 | 0.80 | SYK (0.48) | BTKIKBKBKDM4EPOLBTDP1 | |
| SCHEMBL13765448 | 0.79 | BTK (0.46) | BTKHDAC6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | claimed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | BTK 1/4885IKBKB 50/4885HDAC6 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.